LimmaTech Biologics AG, Schlieren, Switzerland
https://lmtbio.com/

LimmaTech Biologics AG is developing a vaccine to prevent Neisseria gonorrhoeae bacterial infections.

The Neisseria gonorrhoeae (NG) bacterium causes gonorrhea, the second most reported bacterial sexually transmitted infection (STI). Approximately 82 million people were infected in 2020 globally. Patients with gonorrhea can face serious health effects, including pelvic inflammatory disease, chronic pain, infertility, and an increased risk of contracting HIV.

LimmaTech’s vaccine candidate incorporates multiple surface proteins, called antigens, commonly found on NG bacteria. The goal is to develop a single, cost-effective vaccine that can elicit a robust immune response against different NG bacterial strains to help protect patients from around the world.

Resistant NG strains have evaded all but one antibiotic (ceftriaxone). If successful, LimmaTech’s vaccine could prevent the disease, and significantly curb the spread of resistant bacteria.

Current Development Stage: Hit-to-lead

CARB-X Investment: US$2.2 million

Initial CARB-X Investment Date: July 7, 2023